Business context and reporting period
SRX Global Inc. (NYSE American: SRXH) reported on October 6, 2026, that it had entered into a Stock Purchase Agreement with CERo Therapeutics Holdings, Inc. SRX would acquire all outstanding stock of Holdings’ wholly owned operating subsidiary, CERo Therapeutics, Inc. The acquisition is proposed and has not closed.
Financial terms and key metrics
- Stock consideration: At closing, SRX would issue Holdings shares valued at $1 million, with the share count based on the lower of SRX’s closing share price on the trading day before signing or its 20-day VWAP through that date, subject to specified adjustments.
- Debt cancellation: At closing, SRX would forgive and discharge obligations under its Consolidated Note and related loan documents. The note’s original principal was up to $11.67 million; its outstanding principal was approximately $8.25 million as of the report date, plus accrued interest, fees and expenses. Related liens and security documents would be released.
- Assumed liabilities: SRX would assume specified liabilities of approximately $1.56 million and provide related indemnification to Holdings and certain associated persons.
- Note maturity: In connection with signing, the maturity date was extended to five business days after the earlier of closing or valid termination of the purchase agreement.
- Operating results and liquidity: This 8-K does not report revenue, profit, cash flow, margins, or current liquidity metrics.
Material changes versus the prior comparable period
The filing is a transaction announcement, not a periodic financial report; it does not provide comparable-period operating results. The proposed transaction would add CERo Therapeutics, Inc. as a wholly owned subsidiary and, if completed, cancel the Consolidated Note obligations and release related liens.
Outlook, conditions and risks
- Holdings may seek alternative offers during a 30-day go-shop period. Under specified conditions, a Superior Proposal received during that period may be pursued for up to 45 additional days after the go-shop ends; a qualifying proposal must provide for completion no later than March 15, 2027.
- Closing depends on specified conditions, including SRX’s acquisition of Holdings’ Series C, D and E preferred stock and required Series A preferred-holder waivers, consents and/or conversions. Potential minority participation in a post-closing entity was discussed but is not finalized.
- Other conditions include required consents, compliance with covenants, absence of specified material adverse effects, delivery of transaction documents and SRX funding required advances. SRX’s obligations are not subject to a financing condition.
- The agreement provides for reciprocal $750,000 termination fees in specified circumstances. SRX may also owe up to $100,000 of documented transaction expenses following certain breach-related terminations, subject to the agreement’s terms.
- Management cautions that the transaction or an alternative transaction may not be completed. Disclosed risks include missing required consents or creditor settlements, financing and liquidity constraints, debt maturity, default and enforcement risks, changes in SRX share value or liquidity, and disruption to the subsidiary’s operations and relationships.
Important facts for investors to verify
- Whether the go-shop process produces an alternative proposal and whether the agreement remains in effect.
- Progress in satisfying the preferred-stock, consent, funding and other closing conditions, including any definitive minority-participation arrangements.
- The final number of SRX shares to be issued and the final amount of debt, interest, fees and assumed liabilities at closing.
- Any updates on the Consolidated Note’s maturity, repayment or enforcement status if the transaction does not close.
- The final closing date, or any termination and related fee or expense obligations.